At the time of writing, Gilead Sciences, Inc. [GILD] stock is trading at $85.21, up 0.92%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GILD shares have gain 1.51% over the last week, with a monthly amount glided 7.63%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Gilead Sciences, Inc. [NASDAQ: GILD] stock has seen the most recent analyst activity on October 07, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $100 from $78. Previously, Raymond James upgraded its rating to Outperform on July 08, 2024, and kept the price target unchanged to $93. On May 01, 2024, Maxim Group reiterated its Buy rating and revised its price target to $85 on the stock. HSBC Securities upgraded its rating to a Hold but stick to its price target of $69 on April 24, 2024. Truist downgraded its rating to a Hold and reduced its price target to $82 on February 22, 2024. Deutsche Bank started tracking with a Hold rating for this stock on November 09, 2023, and assigned it a price target of $75. In a note dated September 08, 2023, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $88 to $95.
For the past year, the stock price of Gilead Sciences, Inc. fluctuated between $62.07 and $87.86. Currently, Wall Street analysts expect the stock to reach $80.45 within the next 12 months. Gilead Sciences, Inc. [NASDAQ: GILD] shares were valued at $85.21 at the most recent close of the market. An investor can expect a potential drop of -5.59% based on the average GILD price forecast.
Analyzing the GILD fundamentals
According to Gilead Sciences, Inc. [NASDAQ:GILD], the company’s sales were 27.78B for trailing twelve months, which represents an 5.46% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.36%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.05 and Total Capital is 0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 84.56 points at the first support level, and at 83.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 85.63, and for the 2nd resistance point, it is at 86.04.
Ratios To Look Out For
It is important to note that Gilead Sciences, Inc. [NASDAQ:GILD] has a current ratio of 1.14. Also, the Quick Ratio is 0.95, while the Cash Ratio stands at 0.26. Considering the valuation of this stock, the price to sales ratio is 3.82, the price to book ratio is 5.81 and price to earnings (TTM) ratio is 104.14.
Transactions by insiders
Recent insider trading involved Parsey Merdad, Chief Medical Officer, that happened on Oct 01 ’24 when 2000.0 shares were sold. Officer, MERDAD V PARSEY completed a deal on Oct 01 ’24 to buy 2000.0 shares. Meanwhile, Chief Medical Officer Parsey Merdad sold 21246.0 shares on Sep 12 ’24.
